目的探讨Fbxw8对人前列腺癌DU145细胞增殖及对增殖相关基因cyclinA、cyclinB、CDK1、p21和p27表达的影响。方法RT-PCR和Westernblot法验证Fbxw8siRNAs的干扰效率;利用CCK-8检测法检测细胞的增殖能力;流式细胞仪检测细胞周期分布情况;Westernblot法检测细胞增殖相关蛋白CDKl、CDK2、cyclinA、cyclinB、P21、P27的表达。结果Fbxw8siRNAs显著下调DU145细胞中Fbxw8mRNA及蛋白水平的表达(P〈0.01);Fbxw8siRNAs显著抑制DU145细胞增殖活力,其中72h抑制最明显(P〈0.05);流式细胞术分析显示,Fbxw8siRNAs可阻滞细胞于G2/M期,G2/M期细胞百分数由15.32%(controlsiRNA)增加到29.03%(Fbxw8siRNA1)和28.39%(Fbxw8siRNA2);Westernblot结果显示,Fbxw8siRNAs可促进周期蛋白依赖性激酶抑制剂p21、p27的表达,同时下调G2/M期调控蛋白CDKI、CDK2、cyclinA及cyclinB1的表达。结论靶向抑制DU145细胞中Fbxw8的表达可显著抑制细胞的增殖,使阻滞细胞于G2/M期,并且可能是通过下调CDK1、CDK2、cyclinA及cyclinB1的表达,上调P21、P27的表达实现的。
Objective To investigate the effect of F-box and WD repeat domain containing 8 (Fbxw8) on cell proliferation and the expression levels of proliferation-related genes such as cyclinA, cyclinB, cdkl, edk2, p21 and p27 in human prostate cancer DU145 cells. Methods RT-PCR and Western blot were applied to evaluate the interference efficiency of Fbxw8 siR- NAs. The cell proliferation was assessed by CCK-8 assay. The cell cycle of DU-145 cells was determined by flow cytometry. The expression levels of CDK1, CDK2, cyclin A, cyclinB, P21 and P27 proteins were detected by Western blot. Results Fbxw8 siRNA significantly de- creased the mRNA and protein of Fbxw8 in DU145 cells(P 〈0. 01 ). The proliferation of DU- 145 cells was obviously inhibited after Fbxw8 siRNA intervention, especially in 72 h (P 〈 0. 05 ). Flow cytometry analysis showed that Fbxw8 siRNA caused cell cycle arrest in G2/Mphase and cell percent of G2/M phase increased from 15.32% ( control siRNA) to 29.03% (Fbxw8 siRNA 1 ) and 28.39% (Fbxw8 siRNA 2). Westert blot showed that the levels of CDK1, CDK2, CyclinA and CyclinB expression were down-regulated whereas the levels of p21 and p27 were up-regulated. Conclnsion Targeted inhibition of Fbxw8 in DU145 cells can sig- nificantly inhibit cell proliferation and block cells in G2 / M phase, which may be achieved by decreasing the expressions of CDK1, CDK2, cyclin A and cyclin B1 and increasing the expres- sions of P21 and P27.